Skip to main content

Table 1 Drugs that influence ubiquitin-proteasome activity

From: The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

Drug class Action and mechanism
Chemotherapeutic agents  
   Aclarubicin Inhibits the chymotrypsin-like proteolytic activity of the proteasome
   All-trans retinoic acid May accelerate PML fusion protein degradation through the proteasome
   Arsenic trioxide Inhibits ubiquitination and degradation of IκB through effects on the IκB kinase
   Camptothecin Stimulate ubiquitination and degradation of topoisomerase 1
   Geldanamycin Inhibits HSP90 ATPase, stimulating proteasomal degradation of client proteins
   PS-341/LDP-341/MLN-341 Inhibits the chymotrypsin-like activity of the proteasome
   Vinblastine, Vincristine Inhibit the chymotrypsin-like, trypsin-like- and peptidyl-glutamyl peptide hydrolyzing proteasome activities
Immunosuppressive agents  
   Cyclosporine A Uncompetitive inhibitor of the proteasomal chymotrypsin-like activity
   Rapamycin Inhibits proteasome function by inhibiting the proteasome activator PA28
Miscellaneous agents  
   Fulvestrant Stimulates proteasome-dependent proteolysis of ERα
   Tannic acid Inhibits the chymotrypsin-like activity of the proteasome
   Lovastatin Mechanism unknown, but appears structurally similar to the proteasome inhibitor lactacystin
   Anti-retroviral drugs Inhibit the chymotrypsin-like and trypsin-like proteasome activities
  1. ER, estrogen receptor; HSP, heat shock protein; PML, promyelocytic leukemia.